|Day Low/High||0.19 / 0.20|
|52 Wk Low/High||0.15 / 0.65|
Agreement with myTomorrows, Following Success in Netherlands, Seeks to Expand Ampligen Early Access Programs in Pancreatic Cancer into Canada
Scheduled for January 30 at the Keystone Symposia on Molecular and Cellular Biology
Multiple Studies Continue to Demonstrate Broad Immunotherapeutic Properties of Hemispherx's Ampligen
Ampligen® has orphan drug status in the U.S. for treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Transaction helps boost Ampligen production to maximum levels
New Technology Simplifies, Speeds Production of Immuno-Oncology Candidate
Ampligen from Hemispherx Shows Potential to Make Tumors More Responsive to Checkpoint Inhibitors
Earlier Primate Studies Showed Enhanced Protection and Rodent Studies Showed Cross-Protection in Influenza Models
Financials for Second Quarter Ended June 30, 2017 will be released on August 14, 2017
Advocacy Organization to Work with Health Canada with the Goal to Gain Approval
Cytokine Signatures Could Lead to the First Empirical Measure of Disease Severity in Chronic Fatigue Syndrome
12 Pancreatic Cancer Patients Receiving Ampligen® Immuno-Oncology Therapy in Early Access Program
Joseph C. Horvath, M.D., Named Deputy Chief Medical Officer to Oversee Ampligen European Pancreatic Cancer Programs
Promotes Carol Smith, Ph.D., to Chief Manufacturing Officer and Deputy Chief Scientific Officer
The company has generated revenues from the lots of newly manufactured Ampligen
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.